DeciBio

We're excited to kick off the new year with the inaugural Women of Precision Medicine: 25 Perspectives for 2025! This list features 25 exceptional women making an impact as leaders in precision medicine. From women’s health to cancer detection, digital pathology, AI, and beyond, their perspectives address key themes like diagnostic accessibility, equity in genomics, and the promise of multi-omics, emphasizing the transformative contributions of women across the field. This initiative was developed with the contributions of Tina Wang, Katie Maloney, Mané Mikayelyan, Megan Nacar, Kimmi Stacey, and Stephane Budel, whose efforts reflect a shared commitment to amplifying women’s voices and driving meaningful progress in precision medicine. Explore the publication and learn more about how to nominate a WOPM for future initiatives here: https://lnkd.in/gRZxwqFT #WOPM #Leadership #PrecisionMedicine

We wrapped up 2024 with updates and innovation in digital health! Read more here:  Disease Management / Digital Therapeutics  Cleerly raised $106 million to expand its AI-driven CT imaging technology for diagnosing coronary artery disease. Withings received FDA clearance for its BPM Pro 2, a cellular blood pressure monitor that enhances remote patient monitoring and integrates with clinical workflows. Wisp and Nourish collaborate to make nutrition counseling more accessible for women on GLP-1s. Informatics / Healthcare IT Solutions  Carta Healthcare acquired Realyze Intelligence to boost its platform for faster patient matching in oncology research, aiming to improve outcomes and reduce costs. athenahealth introduced AI-driven automation tools to streamline revenue cycle management and cut administrative tasks for healthcare practices. Women’s Health / Femtech  GE HealthCare launched the Pristina Via mammography system to improve workflow and patient care, focusing on reducing repetitive tasks and ensuring flexible, patient-centered care. A study found that women who enrolled in a self-pay, AI-enhanced breast cancer screening program had a 21% higher cancer detection rate compared to unenrolled women, with AI acting as a second reviewer. Check out the newsletter to learn more about these updates in digital health and informatics: https://lnkd.in/gu99n_Y5 Subscribe here to get the next newsletter delivered straight to your inbox: https://lnkd.in/gKQn7_zp These headlines were curated by Katie Schneider, Katherine Erickson, and Emily L.. #DigitalHealth #Informatics #Healthcare #Diagnostics #FemTech

We are thrilled to announce the launch of the Sixth Edition of our Single Cell Analysis report, which states that the global single cell analysis market is expected to reach $2.1B by 2029. There have been numerous developments in the market since the fifth edition was published and we took a completely updated look at the landscape, informed by 100+ interviews and survey responses across academic, biopharma, and CRO stakeholders. We also expanded the report, which now features: · A deep dive into emerging SCA technologies · 30+ pages of survey data that gives an in-depth look at current SCA use, including the adoption of instrument-free assays · Primary vendor feedback on key players in the space Learn more about DeciBio’s Single Cell Analysis Market Report – Sixth Edition: 2024-2029 and download a sample of the report here: https://lnkd.in/gdPKWWci Miguel Edwards, Ph.D., Rebecca Burnham, PhD, Alan Itakura, Emily L. #singlecell #singlecellgenomics #singlecellsequencing #cellanalysis #multiomics

As 2024 comes to an end, December provided a fitting finale to a year of rapid progress in AI for healthcare. Key themes of the final month of 2024 included collaboration, innovation, and the growing integration of AI into healthcare systems. Here's a quick summary: 1. Drug Discovery This month underscored the power of partnerships. Companies like BioAge Labs and Novartis are leveraging AI to target aging-related diseases, while Gilead Sciences and Terray Therapeutics teamed up to advance small molecule therapeutics. Notably, AI Proteins and Bristol Myers Squibb announced a $400M collaboration focusing on miniproteins, signaling increasing industry confidence in AI-driven approaches. 2. Diagnostics Diagnostics saw exciting advancements, including Siemens Healthineers' AI-enhanced imaging tools and Philips' collaboration with icometrix to improve neurological care. Meanwhile, the UK MHRA launched a regulatory pilot for AI-powered medical devices, an important step toward safely integrating these tools into healthcare. 3. Healthcare From Suki's AI-driven workflow improvements to SandboxAQ’s $300M funding round, the focus remains on scaling AI solutions that enhance patient care and operational efficiency. Investments in mental health care, like Cedars-Sinai’s backing of Amae Health, highlight how AI is beginning to address underserved areas in healthcare. As we head into 2025, these developments highlight AI’s growing role in healthcare. Check out the newsletter to learn more about these updates in AI and Machine Learning: https://lnkd.in/g5ruhftF Subscribe here to get the next newsletter delivered straight to your inbox: https://lnkd.in/gKQn7_zp These headlines were curated by Luka Jelcic, Merouane Ounadjela, Eliza French, Katie Schneider, Graham F., and Rebecca Bair. #AI #Diagnostics #DrugDiscovery

We are thrilled to share our latest contribution to Cell & Gene: 2025 Forecast for Advanced Therapies, authored by Sara Ricci, Merouane Ounadjela, and Carl Schoellhammer. 2024 brought recalibration and cautious progress to advanced therapies, with breakthroughs in cell therapies, renewed interest in oligos, and shifting strategies in mRNA and AAV technologies. As we enter 2025, our team explores what lies ahead. Dive into the full article here: https://lnkd.in/gGXk-9HC What are you most excited about for advanced therapies in 2025? Share your thoughts in the comments! #AdvancedTherapies #CellAndGene #Biopharma

December was an exciting month for the next-generation therapeutics field. In the Cell Therapy space, Altaris, LLC announced their acquisition of WuXi AppTec's U.S. and U.K.-based cell therapy manufacturing business and Bristol Myers Squibb announced cancellations of their partnerships with Century Therapeutics, Inc and Immatics. There were also a handful of clinical trial updates, with Arcellx reporting positive iMMagine-1 data for their multiple myeloma treatment and Gilead Sciences reporting follow-up data for Tecartus at ASH. Multiple clinical trial updates were announced in the Gene Therapy space in December, with Capsida Biotherapeutics releasing preclinical data for an epilepsy candidate, HuidaGene Therapeutics dosing their first patient in a MECP2 Duplication Syndrome trial, SpliceBio announcing IND clearance for their Phase ½ ASTRA study, and Atsena Therapeutics announcing the completion of dosing in Part A of their Phase 1/2 LIGHTHOUSE study.   In the Oligo space, Silexion Therapeutics Corp and Evonik announced a collaboration for advanced siRNA formulation. In addition, a number of clinical trial updates were announced, including #SiriusTherapeutics’ announcement of promising preliminary data of a Phase 1 trial with SRSD107, Silence Therapeutics plc’s announcement of efficacy data in the Phase 1 SANRECO study, and Ractigen Therapeutics’s successful first patient dosing in a Phase 1 trial of RAG-17.    In the ADC space, Gilead and Tubulis GmbH announced a partnership to develop ADCs targeting solid tumors, while Elevation Oncology partnered with Lonza’s Synaffix BV to develop a HER3-directed ADC. Daiichi Sankyo US also announced their $152M investment in a manufacturing plant in China and Aadi Bioscience, Inc pivoted from a commercial-stage company to a preclinical biotech. Read on to see additional developments that occurred in December here: https://lnkd.in/grx3ZerW What do you expect to occur in 2025? Please take our CGT Sentiment Survey with your thoughts:  https://lnkd.in/gd_UQk7A Subscribe to our newsletter on Linkedin: https://lnkd.in/gMfy6_YZ Sign up to receive our Next-Generation Therapeutics Newsletter in your email: https://lnkd.in/gKQn7_zp These headlines were curated by Carl Schoellhammer, Rebecca Burnham, PhD, Juilee Malavade, Ph.D., Hannah Glazier, Phillip Leclair, and Ben Yarovinsky. #precisionmedicine #nextgenerationtherapeutics #celltherapy #genetherapy #oligotherapy #biotechnology

How well did you keep up with the precision medicine space in 2024? Celebrate the holiday season by putting your knowledge to the test! Download or play our 2024 Year-in-Review Crossword Puzzle online to challenge your mastery of the field. The first to finish it wins serious bragging rights! Happy holidays to all our friends, colleagues, and partners. A huge thank you to our in-house puzzle wizard, Graham F., for making it possible. Access the puzzle online here: https://lnkd.in/gfa-hpdX #YearinReview #PrecisionMedicine #CrosswordPuzzleChallenge

We’re sending out a contingent to San Francisco for the 2025 JPM Healthcare Week! From January 12-16, our team of partners, project leaders, and industry experts will be ready to discuss the evolving precision medicine market– spanning next generation sequencing, spatial biology, infectious disease, bioinformatics, digital pathology, radiomics, early cancer detection, liquid biopsy, advanced therapies, and women’s health. If you're attending, let’s connect and explore how our insights and strategies can help drive your next commercial launch. #JPM2025 #PrecisionMedicine

Ah, can’t believe the New Year is just around the corner and that this event is just next month! I'm looking forward to moderating the PDA West Coast Chapter (PDA WCC) 10th Annual Women in Life Sciences Panel next month at Genentech in South San Francisco on January 30, 2025. This event's theme focuses on Empowerment, creating an environment where women feel confident, supported, and equipped to thrive. It’s always inspiring to hear stories and insights from women leaders who’ve navigated the unique challenges of our industry. I’m especially excited to help foster discussions that invite both men and women to join the conversation about uplifting and empowering women in life sciences. Early bird tickets are available until December 20! Hope to see you there: https://lnkd.in/g9SW5CEY Also if you're in the Bay, that following Sunday Feb 2 - I'll be riding with Cycle for Survival at the Palo Alto Equinox. Ping me if you'd like to join and support rare cancer research!

Meet David Cavanaugh! David Cavanaugh is the co-founder of DeciBio Consulting, where he actively engages in the firm’s consulting, data, and venture capital activities. With a strong passion for advancing precision medicine, he is particularly excited about extending its applications beyond oncology into other therapeutic areas. In his free time, David enjoys running, exploring new cultures through international travel, indulging in diverse cuisines, and cherishing moments with his husband and their chiweenie, Didier! Meet with David at the upcoming JPM Conference, from January 13-16 in San Fransisco, CA. Learn more about our DxBooks here: https://lnkd.in/gX66v7HD Want to be a part of our team? Check out our open positions or learn more about us on our website: https://lnkd.in/gteq7n_F #meettheteam #precisionmedicine